JP4373675B2
(ja)
*
|
2001-03-22 |
2009-11-25 |
ソルベイ・フアーマシユーチカルズ・ベー・ブイ |
Cb1−拮抗活性を有する4,5−ジヒドロ−1h−ピラゾール誘導体
|
US20050054730A1
(en)
*
|
2001-03-27 |
2005-03-10 |
The Regents Of The University Of California |
Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
|
RU2286988C2
(ru)
|
2001-09-21 |
2006-11-10 |
Солвей Фармасьютикалс Б.В. |
Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью
|
TWI231757B
(en)
|
2001-09-21 |
2005-05-01 |
Solvay Pharm Bv |
1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
|
HUP0401567A3
(en)
*
|
2001-09-21 |
2005-06-28 |
Solvay Pharm Bv |
Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
|
DE60334787D1
(de)
|
2002-03-12 |
2010-12-16 |
Merck Sharp & Dohme |
Substituierte amide
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
GB0216700D0
(en)
|
2002-07-18 |
2002-08-28 |
Astrazeneca Ab |
Process
|
ES2301833T3
(es)
*
|
2002-07-29 |
2008-07-01 |
Hoffmann La Roche |
Derivados de benzodioxol.
|
US7765162B2
(en)
*
|
2002-10-07 |
2010-07-27 |
Mastercard International Incorporated |
Method and system for conducting off-line and on-line pre-authorized payment transactions
|
WO2004035566A1
(en)
*
|
2002-10-18 |
2004-04-29 |
Pfizer Products Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7129239B2
(en)
*
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
US7247628B2
(en)
*
|
2002-12-12 |
2007-07-24 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
MXPA05007114A
(es)
|
2003-01-02 |
2005-08-26 |
Hoffmann La Roche |
Nuevos agonistas inversos del receptor cb1.
|
CN100360527C
(zh)
|
2003-01-02 |
2008-01-09 |
霍夫曼-拉罗奇有限公司 |
Cb1受体反激动剂
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US7329658B2
(en)
*
|
2003-02-06 |
2008-02-12 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
GB0302673D0
(en)
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
US7176210B2
(en)
*
|
2003-02-10 |
2007-02-13 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7141669B2
(en)
*
|
2003-04-23 |
2006-11-28 |
Pfizer Inc. |
Cannabiniod receptor ligands and uses thereof
|
US20040214856A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US7268133B2
(en)
*
|
2003-04-23 |
2007-09-11 |
Pfizer, Inc. Patent Department |
Cannabinoid receptor ligands and uses thereof
|
US7145012B2
(en)
*
|
2003-04-23 |
2006-12-05 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
BRPI0410289A
(pt)
*
|
2003-05-07 |
2006-05-16 |
Pfizer Prod Inc |
ligantes do receptor de canabinóides e suas utilizações
|
US7232823B2
(en)
|
2003-06-09 |
2007-06-19 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
EP1641779A1
(en)
*
|
2003-06-18 |
2006-04-05 |
AstraZeneca AB |
2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
|
US20040259887A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
GB0314049D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
KR100809201B1
(ko)
|
2003-06-20 |
2008-02-29 |
에프. 호프만-라 로슈 아게 |
카나바노이드 수용체 1 역작용제로서 2-아미노벤조티아졸
|
AR045533A1
(es)
*
|
2003-09-02 |
2005-11-02 |
Solvay Pharm Gmbh |
Uso de un compuesto antagonista de receptor de cb1, composicion farmaceutica y metodo de tratamiento y/o profilaxis de enfermedades relacionadas con dicho receptor de cb1
|
RU2006110545A
(ru)
*
|
2003-09-02 |
2007-10-10 |
Зольвай Фармасьютикалз Гмбх (De) |
Новое медицинское применение избирательных антагонистов св1-рецептора
|
US20050239859A2
(en)
*
|
2003-09-03 |
2005-10-27 |
Solvay Pharmaceuticals Gmbh |
Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
|
TW200528102A
(en)
*
|
2003-10-24 |
2005-09-01 |
Solvay Pharm Gmbh |
Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
|
US20050124660A1
(en)
*
|
2003-10-27 |
2005-06-09 |
Jochen Antel |
Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
|
US20050143441A1
(en)
*
|
2003-10-27 |
2005-06-30 |
Jochen Antel |
Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
|
GB0327331D0
(en)
*
|
2003-11-25 |
2003-12-31 |
Astrazeneca Ab |
Therapeutic agents
|
JP4527729B2
(ja)
|
2003-12-08 |
2010-08-18 |
エフ.ホフマン−ラ ロシュ アーゲー |
新規チアゾール誘導体
|
WO2005075450A2
(en)
|
2004-01-28 |
2005-08-18 |
F. Hoffmann-La Roche Ag |
Spiro-benzodioxoles and their use as cb1 antagonists
|
US7745476B2
(en)
|
2004-01-30 |
2010-06-29 |
Solvay Pharmaceuticals B.V. |
1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
|
DK1713475T3
(da)
*
|
2004-01-30 |
2008-12-01 |
Solvay Pharm Bv |
1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet
|
TW200533657A
(en)
|
2004-02-17 |
2005-10-16 |
Esteve Labor Dr |
Substituted pyrazoline compounds, their preparation and use as medicaments
|
GB0403780D0
(en)
*
|
2004-02-20 |
2004-03-24 |
Astrazeneca Ab |
Therapeutic agents
|
EP2305352A1
(en)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
|
AU2005229459B9
(en)
|
2004-04-03 |
2009-01-22 |
Astrazeneca Ab |
Therapeutic agents
|
BRPI0510679A
(pt)
|
2004-05-10 |
2007-12-26 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos
|
ITMI20041032A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
ITMI20041033A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Composti farmaceutici
|
TW200602314A
(en)
|
2004-05-28 |
2006-01-16 |
Tanabe Seiyaku Co |
A novel pyrrolidine compound and a process for preparing the same
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
CA2581596A1
(en)
*
|
2004-09-29 |
2006-04-13 |
Schering Corporation |
Combinations of substituted azetidonones and cb1 antagonists
|
CA2585175A1
(en)
*
|
2004-10-25 |
2006-05-04 |
Solvay Pharmaceuticals Gmbh |
Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
|
RU2394027C2
(ru)
|
2004-10-27 |
2010-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Новые индольные или бензимидазольные производные
|
EP1812418B1
(en)
|
2004-11-09 |
2010-10-27 |
F. Hoffmann-La Roche AG |
Dibenzosuberone derivatives
|
WO2006060211A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives for the treatment of sexual dysfunction
|
WO2006060201A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives for the treatment of psychiatric disorders
|
WO2006060192A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives
|
WO2006060186A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives for the treatment of dementia and related disorders
|
RU2404164C2
(ru)
|
2005-04-06 |
2010-11-20 |
Ф.Хоффманн-Ля Рош Аг |
Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
|
EP1890767A2
(en)
*
|
2005-05-27 |
2008-02-27 |
Pfizer Products Inc. |
Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
|
US7923465B2
(en)
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
CA2613678A1
(en)
|
2005-06-02 |
2006-12-07 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
EP1749820A1
(en)
*
|
2005-07-15 |
2007-02-07 |
Laboratorios Del Dr. Esteve, S.A. |
Salts of substituted pyrazoline compounds, their preparation and use as medicaments
|
ES2326725B1
(es)
*
|
2005-07-15 |
2010-05-11 |
Laboratorios Del Dr. Esteve, S.A. |
Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.
|
EP1749526A1
(en)
*
|
2005-07-15 |
2007-02-07 |
Laboratorios Del Dr. Esteve, S.A. |
Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
|
EP1743890A1
(en)
*
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
|
EP1749821A1
(en)
*
|
2005-07-15 |
2007-02-07 |
Laboratorios Del Dr. Esteve, S.A. |
Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments
|
ES2330992B1
(es)
*
|
2005-07-15 |
2010-07-06 |
Laboratorios Del Dr. Esteve, S.A. |
Compuestos de pirazolina heterociclilsustituidos, su preparacion y uso como medicamentos.
|
ES2326460B1
(es)
*
|
2005-07-15 |
2010-04-19 |
Laboratorios Del Dr. Esteve, S.A. |
Sales de amonio cuaternario de compuestos de pirazolina sustituidos, su preparacion y uso como medicamentos.
|
US7829581B2
(en)
|
2005-07-15 |
2010-11-09 |
Laboratorios Del Dr. Esteve, S.A. |
Prodrugs of pyrazoline compounds, their preparation and use as medicaments
|
EP1743892A1
(en)
|
2005-07-15 |
2007-01-17 |
Laboratorios del Dr. Esteve S.A. |
Substituted pyrazoline compounds, their preparation and use as medicaments
|
AU2006281368A1
(en)
*
|
2005-08-17 |
2007-02-22 |
Solvay Pharmaceuticals Gmbh |
Method of using potassium channel inhibiting compounds
|
JP4658134B2
(ja)
|
2005-10-04 |
2011-03-23 |
田辺三菱製薬株式会社 |
光学活性4−ヒドロキシ−1,2,3,4−テトラヒドロキノリン化合物の製法
|
AR056560A1
(es)
|
2005-10-06 |
2007-10-10 |
Astrazeneca Ab |
Pirrolopiridinonas como moduladores cb1
|
AU2006328483A1
(en)
*
|
2005-12-20 |
2007-06-28 |
Solvay Pharmaceuticals B.V. |
4,5-dihydro- (1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
|
EP2026798A1
(en)
*
|
2006-04-27 |
2009-02-25 |
Solvay Pharmaceuticals GmbH |
Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
|
US7763607B2
(en)
|
2006-04-27 |
2010-07-27 |
Solvay Pharmaceuticals Gmbh |
Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
|
US20070254863A1
(en)
*
|
2006-04-27 |
2007-11-01 |
Jochen Antel |
Use of CBx cannabinoid receptor modulators as potassium channel modulators
|
ES2389569T3
(es)
*
|
2006-05-05 |
2012-10-29 |
Jenrin Discovery |
Antagonistas/agonistas inversos de receptores de cannabinoides
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
US7964728B2
(en)
*
|
2006-07-06 |
2011-06-21 |
Solvay Pharmaceuticals B.V. |
Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
|
EP2061767B1
(de)
|
2006-08-08 |
2014-12-17 |
Sanofi |
Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
|
US7781593B2
(en)
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
SA07280510B1
(ar)
*
|
2006-09-22 |
2012-02-07 |
سولفاي فارماسوتيكالز بي . في |
سلفونيل بيرازول ومشتقات سلفونيل كربوكساميدين كمضادات ht6-5
|
CA2673359A1
(en)
*
|
2006-12-18 |
2008-06-26 |
7Tm Pharma A/S |
Cb1 receptor modulators
|
AU2008261102B2
(en)
|
2007-06-04 |
2013-11-28 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7655685B2
(en)
*
|
2007-11-02 |
2010-02-02 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
US8470841B2
(en)
|
2008-07-09 |
2013-06-25 |
Sanofi |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
EP2151234A1
(en)
*
|
2008-07-28 |
2010-02-10 |
Laboratorios Del. Dr. Esteve, S.A. |
Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
|
AR072539A1
(es)
*
|
2008-08-01 |
2010-09-01 |
Solvay Pharm Bv |
Sintesis de derivados de 3,4-diaril -4,5-dihidro -(1h) - pirazol -1- carboxamida
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
WO2010079241A1
(es)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
RU2012111354A
(ru)
|
2009-08-26 |
2013-10-10 |
Санофи |
Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
|
WO2011044370A1
(en)
|
2009-10-07 |
2011-04-14 |
Jenrin Discovery |
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
EP2640381A4
(en)
|
2010-11-18 |
2014-05-21 |
Jenrin Discovery |
CANNABINOID RECEPTOR ANTAGONISTS / INVERSAGONISTS FOR THE TREATMENT OF METABOLISM DISEASES INCLUDING ADIPOSITAS AND DIABETES
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
CN105001219A
(zh)
|
2011-02-25 |
2015-10-28 |
默沙东公司 |
用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683700B1
(de)
|
2011-03-08 |
2015-02-18 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8846666B2
(en)
|
2011-03-08 |
2014-09-30 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2683703B1
(de)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8680131B2
(en)
|
2012-07-25 |
2014-03-25 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
|
EA027174B1
(ru)
|
2012-08-01 |
2017-06-30 |
Льюис Энд Кларк Фармасьютикалз, Инк. |
N-алкил 2-(дизамещенные)алкиниладенозин-5-уронамиды в качестве a-агонистов
|
WO2014022528A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US11155521B2
(en)
|
2012-11-13 |
2021-10-26 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Cannabinoid receptor mediating compounds
|
JP6272626B2
(ja)
|
2012-11-13 |
2018-01-31 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
カンナビノイド受容体媒介性化合物
|
JP2016516004A
(ja)
|
2013-02-22 |
2016-06-02 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗糖尿病二環式化合物
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
KR102272746B1
(ko)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
JP6762930B2
(ja)
*
|
2014-05-09 |
2020-09-30 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
カンナビノイド受容体メディエータとしてのピラゾール誘導体およびそれらの使用
|
EP3109237A1
(en)
|
2015-06-22 |
2016-12-28 |
AnaMar AB |
Novel 5-ht2 antagonists
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
EP4341246A1
(en)
|
2021-05-17 |
2024-03-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
A facile and odor-free approach to convert sulfonyl urea derivatives to chalcogenide sulfonyl urea derivatives
|